Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study
Diabetologia · 2024
DOI: 10.1007/s00125-024-06220-6 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Diabetologia, 2024. Verfasst von Bibi U Nielsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Centre Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. bibi.uhre…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Insulin Resistance, Insulin, Glucose Tolerance Test. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, CF-Trust, US Public Health Service.
Abstract (Originalsprache)
Aims/hypothesis The aim of this study was to investigate insulin secretion, insulin sensitivity, disposition index and insulin clearance by glucose tolerance status in individuals with cystic fibrosis (CF) and exocrine pancreatic insufficiency.
Methods
In a cross-sectional study, we conducted an extended (ten samples) OGTT in individuals with pancreatic-insufficient CF (PI-CF). Participants were divided into normal glucose tolerance (NGT), early glucose intolerance (EGI), impaired glucose tolerance (IGT) and CF-related diabetes (CFRD) groups. We used three different oral minimal models to assess insulin secretion, insulin sensitivity and insulin clearance during the OGTT. We evaluated insulin secretion using total secretion (Φ total), first-phase secretion (Φ dynamic) and second-phase secretion (Φ static) from the model, and we estimated the disposition index by multiplying Φ total and insulin sensitivity.
Results
Among 61 participants (NGT 21%, EGI 33%, IGT 16%, CFRD 30%), insulin secretion indices (Φ total, dynamic and static) were significantly lower in the CFRD group compared with the other groups. Insulin sensitivity declined with worsening in glucose tolerance ( p value for trend
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cystic Fibrosis Centre Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. bibi.uhre.nielsen.01@regionh.dk.
- Cystic Fibrosis Centre Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Infectious Diseases, Copenhagen University Hospital - Hvidovre, Copenhagen, Denmark.
- Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
- Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, and Institute for Diabetes, Obesity & Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Förderung
- NIDDK NIH HHS
- CF-Trust
- US Public Health Service
- National Hospital
Zitieren
APA
Nielsen, B. U., Mathiesen, I. H. M., Krogh-Madsen, R., Katzenstein, T. L., Pressler, T., Shaw, J. A. M., Rickels, M. R., Almdal, T. P., Faurholt-Jepsen, D., & Stefanovski, D. (2024). Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study. Diabetologia. https://doi.org/10.1007/s00125-024-06220-6
Vancouver
Nielsen BU, Mathiesen IHM, Krogh-Madsen R, Katzenstein TL, Pressler T, Shaw JAM, et al. Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study. Diabetologia. 2024. doi:10.1007/s00125-024-06220-6
BibTeX
@article{Nielsen2024,
author = {Nielsen, Bibi U and Mathiesen, Inger H M and Krogh-Madsen, Rikke and Katzenstein, Terese L and Pressler, Tacjana and Shaw, James A M and Rickels, Michael R and Almdal, Thomas P and Faurholt-Jepsen, Daniel and Stefanovski, Darko},
title = {Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06220-6}
}
EUVIMED